122 related articles for article (PubMed ID: 34353271)
21. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.
Kathawala RJ; Wang YJ; Shukla S; Zhang YK; Alqahtani S; Kaddoumi A; Ambudkar SV; Ashby CR; Chen ZS
Chin J Cancer; 2015 Mar; 34(3):115-20. PubMed ID: 25962593
[TBL] [Abstract][Full Text] [Related]
22. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
23. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
24. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Oba T; Izumi H; Ito KI
Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the anti-proliferative activity of three new pyrazole compounds in sensitive and resistant tumor cell lines.
Viale M; Anzaldi M; Aiello C; Fenoglio C; Albicini F; Emionite L; Gangemi R; Balbi A
Pharmacol Rep; 2013; 65(3):717-23. PubMed ID: 23950595
[TBL] [Abstract][Full Text] [Related]
26. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
27. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
28. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.
Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N
Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494
[TBL] [Abstract][Full Text] [Related]
29. FaDu cell characteristics induced by multidrug resistance.
Ma J; Lu S; Yu L; Tian J; Li J; Wang H; Xu W
Oncol Rep; 2011 Nov; 26(5):1189-95. PubMed ID: 21833476
[TBL] [Abstract][Full Text] [Related]
30. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
31. Heat shock genes - integrating cell survival and death.
Arya R; Mallik M; Lakhotia SC
J Biosci; 2007 Apr; 32(3):595-610. PubMed ID: 17536179
[TBL] [Abstract][Full Text] [Related]
32. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
33. In vitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320 cells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibition.
Balachandran C; Emi N; Arun Y; Yamamoto N; Duraipandiyan V; Inaguma Y; Okamoto A; Ignacimuthu S; Al-Dhabi NA; Perumal PT
Chem Biol Interact; 2016 Apr; 249():23-35. PubMed ID: 26915975
[TBL] [Abstract][Full Text] [Related]
34. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
35. An investigation of heat shock protein 27 and P-glycoprotein mediated multi-drug resistance in breast cancer using liquid chromatography-tandem mass spectrometry-based targeted proteomics.
Xu F; Yang T; Fang D; Xu Q; Chen Y
J Proteomics; 2014 Aug; 108():188-97. PubMed ID: 24882106
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
Lv F; Yu Y; Zhang B; Liang D; Li ZM; You W
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):870-876. PubMed ID: 24337851
[TBL] [Abstract][Full Text] [Related]
38. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.
Wang N; Wang Z; Peng C; You J; Shen J; Han S; Chen J
Carcinogenesis; 2014 Nov; 35(11):2544-54. PubMed ID: 25194164
[TBL] [Abstract][Full Text] [Related]
39. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
40. A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter.
Rao DK; Liu H; Ambudkar SV; Mayer M
J Biol Chem; 2014 Nov; 289(45):31397-410. PubMed ID: 25253691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]